Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 145Neoplasm Metastasis 16Advanced Breast Cancer 9Neoplasms 8Ovarian Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Breast Cancer Metastatic 5Prostatic Neoplasms 4Endometrial Neoplasms 4Recurrence 3Hereditary Sensory and Autonomic Neuropathies 3Lung Neoplasms 2Hyperglycemia 2Exanthema 2Estrogen Receptor-positive Breast Cancer 2Colorectal Neoplasms 2Carcinoma, Lobular 2Breast Neoplasms, Male 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sex Cord-Gonadal Stromal Tumors 1Sarcoma, Endometrial Stromal 1Salivary Gland Neoplasms 1Recurrent Uterine Corpus Carcinoma 1Neoplastic Cells, Circulating 1

Interventions

capivasertib 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × CCCA Assessed by Ki67 Drop Below <2.7% From Baseline × Fulvestrant × Clear all
NCT06607757 2025-04-02

Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer

GBG Forschungs GmbH

Phase 2 Recruiting
120 enrolled

CCCA Assessed by Ki67 Drop Below <2.7% From Baseline

Data powered by HemOnc (CC BY 4.0) Colophon âš¡